Buchumschlag

Long-term safety and effectiveness of Rezafungin treatment in candidemia and invasive candidiasis: results from an early access program in Italy and Germany

Outcomes are reported for 6 adults receiving rezafungin for chronic, hard-to-treat, invasive candidiasis (including Candida parapsilosis) during an early access program. Rezafungin was well tolerated and administered via once-weekly outpatient intravenous infusion for up to 39 weeks during the progr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Trapani, Filippo (VerfasserIn) , Viceconte, Giulio (VerfasserIn) , Morena, Valentina (VerfasserIn) , Tiseo, Giusy (VerfasserIn) , Mori, Giovanni (VerfasserIn) , Kölking, Britta (VerfasserIn) , Khatamzas, Elham (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: March 2025
In: Open Forum Infectious Diseases
Year: 2025, Jahrgang: 12, Heft: 3, Pages: 1-6
ISSN:2328-8957
DOI:10.1093/ofid/ofaf034
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1093/ofid/ofaf034
Volltext
Verfasserangaben:Filippo Trapani, Giulio Viceconte, Valentina Morena, Giusy Tiseo, Giovanni Mori, Britta Kölking, and Elham Khatamzas
Beschreibung
Zusammenfassung:Outcomes are reported for 6 adults receiving rezafungin for chronic, hard-to-treat, invasive candidiasis (including Candida parapsilosis) during an early access program. Rezafungin was well tolerated and administered via once-weekly outpatient intravenous infusion for up to 39 weeks during the program, enabling hospital discharge and replacing daily antifungal infusions.
Beschreibung:Veröffentlicht: 19. März 2025
Gesehen am 19.08.2025
Beschreibung:Online Resource
ISSN:2328-8957
DOI:10.1093/ofid/ofaf034

Ähnliche Einträge